株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

先端巨大症:パイプライン製品の分析

Acromegaly - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 192431
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.28円で換算しております。
Back to Top
先端巨大症:パイプライン製品の分析 Acromegaly - Pipeline Review, H1 2017
出版日: 2017年04月28日 ページ情報: 英文 80 Pages
概要

先端巨大症は、成人期に下垂体で成長ホルモンが過剰に生成される場合に発症するホルモン障害です。体臭、疲れやすい、頭痛、巨大な足、過剰な身長、関節周囲の骨の部位の腫れ、歯の間隔が広い、睡眠時無呼吸などの症状が見られます。治療には、外科手術、ドーパミン作動薬、成長ホルモン拮抗薬などが含まれます。

当レポートでは、先端巨大症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

先端巨大症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Aegis Therapeutics, LLC
  • Antisense Therapeutics Limited
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Foresee Pharmaceuticals, LLC
  • Glide Pharmaceutical Technologies Limited
  • Ionis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Italfarmaco S.p.A.
  • Novartis AG
  • Peptron, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ATL-1103
  • BIM-23A758
  • COR-005
  • FP-002
  • G-02113
  • ISIS-GHRLRx
  • ITF-2984
  • L-779976
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate long acting
  • octreotide acetate SR
  • octreotide SR
  • pasireotide ER
  • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors
  • Somadex
  • SXN-101742
  • SXN-101959

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9189IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H1 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 8 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acromegaly - Overview
    • Acromegaly - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Acromegaly - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Acromegaly - Companies Involved in Therapeutics Development
    • Aegis Therapeutics LLC
    • Amryt Pharma plc
    • Antisense Therapeutics Ltd
    • Chiasma Inc
    • Crinetics Pharmaceuticals Inc
    • Daewoong Pharmaceutical Co Ltd
    • Dauntless Pharmaceuticals Inc
    • DexTech Medical AB
    • Foresee Pharmaceuticals LLC
    • Glide Pharmaceutical Technologies Ltd
    • Ionis Pharmaceuticals Inc
    • Ipsen SA
    • Italfarmaco SpA
    • Midatech Pharma Plc
    • Novartis AG
    • Peptron Inc
    • Silence Therapeutics Plc
    • Strongbridge Biopharma plc
    • Sun Pharma Advanced Research Company Ltd
  • Acromegaly - Drug Profiles
    • Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atesidorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIM-23B065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-GHRLRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITF-2984 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-779976 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate long acting - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Somadex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SXN-101959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veldoreotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acromegaly - Dormant Projects
  • Acromegaly - Discontinued Products
  • Acromegaly - Product Development Milestones
    • Featured News & Press Releases
      • Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
      • Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
      • Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
      • Dec 02, 2016: Amryt Pharma provides update on AP-102
      • Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
      • Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation
      • Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
      • Jul 13, 2016: ATL1103 Patent Update
      • Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
      • Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
      • Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
      • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
      • May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
      • May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
      • Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acromegaly, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Acromegaly - Pipeline by Aegis Therapeutics LLC, H1 2017
  • Acromegaly - Pipeline by Amryt Pharma plc, H1 2017
  • Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2017
  • Acromegaly - Pipeline by Chiasma Inc, H1 2017
  • Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2017
  • Acromegaly - Pipeline by DexTech Medical AB, H1 2017
  • Acromegaly - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Acromegaly - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
  • Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Acromegaly - Pipeline by Ipsen SA, H1 2017
  • Acromegaly - Pipeline by Italfarmaco SpA, H1 2017
  • Acromegaly - Pipeline by Midatech Pharma Plc, H1 2017
  • Acromegaly - Pipeline by Novartis AG, H1 2017
  • Acromegaly - Pipeline by Peptron Inc, H1 2017
  • Acromegaly - Pipeline by Silence Therapeutics Plc, H1 2017
  • Acromegaly - Pipeline by Strongbridge Biopharma plc, H1 2017
  • Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Acromegaly - Dormant Projects, H1 2017
  • Acromegaly - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Acromegaly, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top